ABL Bio enters Grabody-B brain delivery platform license pact with GSK to develop novel medicines for neurodegenerative diseases: Seongnam, South Korea Tuesday, April 8, 2025, 17: ...

Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.

Steen Lisby, M.D., D.MSc. joins as Chief Medical OfficerJesper Valbjørn, M.Sc. joins as Senior Vice President CMCOngoing team expansion at Myricx ...

Equities research analysts at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a report released on Tuesday. The firm set a “hold” rating on the ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier (BBB) penetrating ...

UK biotech Epsilogen has bought US-based TigaTx, pooling their resources to create what it says will be a leader in ...

Merus leads biotech with its innovative antibody platforms, strong financials, and promising petosemtamab targeting cancer.

ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology ...

Highlights The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen's assets and expertise in IgE to create the world's leading pan-isotype cancer antibody ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

Global Bispecific Trispecific Antibodies Market Size Will Surpass US$ 50 Billion By 2030 Says Kuick ResearchDelhi, April 04, ...

The primary end point of overall response rate has been met in the COMPANION-002 trial of tovecimig and paclitaxel in ...